Aeovian Pharmaceuticals is a startup based in the United States, most recent round Series B, 1 tracked investor.
Based in the United States, Aeovian Pharmaceuticals is a startup. Its most recent tracked round is Series B. Brouky records 1 investor associated with the company.
Aeovian Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted and highly selective small molecules to restore cellular metabolic quality control, addressing dysregulated growth and hyperactive signaling in rare genetic and age-related diseases. Its lead candidate, AV078, is a first-in-class CNS-penetrant selective inhibitor of mTOR complex 1 (mTORC1) for treating tuberous sclerosis complex (TSC) refractory epilepsy.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.